Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda,
Correspondence to Dr Nathan Ford, MPH, PhD,
Centre for Infectious Diseases Epidemiology and
Research, University of Cape Town, Anzio Road Cape
Town 7925, South Africa.
Received: 5 August 2011; revised: 26 August 2011;
accepted: 7 September 2011.
1. WHO. Antiretroviral therapy for HIV infection in adults and
adolescents. Recommendations for a public health approach
2010 revision. Geneva: World Health Organization; 2010.
2. Lewis-Hall F. Important change in SUSTIVA (efavirenz) package
insert: change from category C to D. 2005. Bristol-Myers Squibb
3. Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al.
Safety of efavirenz in ﬁrst-trimester of pregnancy: a systematic
review and meta-analysis of outcomes from observational
cohorts. AIDS 2010; 24:1461–1470.
4. Phanuphak N, Teeratakulpisarn S, Chinmahun A, Ooprasithi-
wong J, Mathajittiphun P, Jittarach K, et al. Efﬁcacy and safety of
maternal triple-drug ARV regimens: Thai Red Cross PMTCT
Program, 2004 to 2010. 18th Conference on Retroviruses and
Opportunistic Infections; February 2011; Boston, Massachu-
setts. Abstract 742.
5. Cressey T, Stek A, Capparelli E, Bowonwatanunwong C, Prom-
mas S, Huo Y, Read J, Smith E, Best B, Morichnick M, IMPAACT
P1026 s team. Efavirenz pharmacokinetics during the 3rd
trimester of pregnancy and postpartum. 18th Conference
on Retroviruses and Opportunistic Infections; February 2011;
Boston, Massachusetts. Abstract 754.
6. Areechokchai D, Bowonwatanuwong C, Phonrat B, Pitisut-
tithum P, Maek ANW. Pregnancy outcomes among HIV-
infected women undergoing antiretroviral therapy. Open AIDS
J 2009; 3:8–13.
7. Blood E, Beckwith C, Bazerman L, Cu-Uvin S, Mitty J. Preg-
nancy among HIV-infected refugees in Rhode Island. AIDS
Care 2009; 21:207–211.
8. Oliveira M. Pharmacovigilance of antiretroviral drugs in carry-
ing pregnant women of HIV and children displayed to the HIV
during the gestation in use of prophylaxis of the vertical
transmission: study incidence pilot [masters thesis]. Instituto
de Pesquisa Clı´nica Evandro Chagas: Rio de Janeiro, Brazil;
2007. pp. 123.
9. Ekouevi DK, Cofﬁe PA, Ouattara E, Moh R, Amani-Bosse C,
Messou E, et al. Pregnancy outcomes in women exposed to
efavirenz and nevirapine: an appraisal of the IeDEA West
Africa and ANRS Databases, Abidjan, Cote d’Ivoire. J Acquir
Immune Deﬁc Syndr 2011; 56:183–187.
10. Cofﬁe P, Moh P, Tonwe-Gold B, Amani-Bosse C, Messou E,
Gabillard D, et al. Birth outcomes among women exposed to
efavirenz in Abidjan, Ivory Coast. 5th Francophone Conference
on HIV/AIDS, Casablanca, Morocco, 28–31 March 2010:
11. Antiretroviral Pregnancy Registry Steering Committee. Antire-
troviral Pregnancy Registry international interim report for 1
January 1989 through 31 January 2011. Wilmington, NC: Reg-
istry Coordinating Center; 2011. http://www.APRegistry.com.
[Accessed 1 July 2011].
12. Joao E, Calvet G, Cunha C, Menezes J, Martins E, Medeiros A,
et al. Pregnancy outcome in women exposed to efavirenz, XVI
International AIDS Conference; 13–18 August 2006; Toronto,
Canada. Abstract CDB0698.
13. Gonzalez-Tome M, Fernandez-Ibieta M, Ramos AJ, Munoz-
Galligo E, Rojo C, Nieto O, et al. The Spanish cohort of
HIV-infected mother -infant pairs. Efavirenz in pregnancy:
maternal characteristics of women who become pregnant on
EFV-containing regimen and neonatal effects. XVII International
AIDS Conference 3-8 August 2008, Mexico City, Mexico.
14. Westreich D, Robel D, MacDonald P, Majuba P, Maskew M,
Nagar S, Jaffray I, MacPhail Abstract P, Cole S, Sanne I. Preg-
nancy, efavirenz, and birth outcomes in Johannesburg 17th
Conference on Retroviruses and Opportunistic Infections, San
Francisco; 2010. Abstract 922.
15. Bera E, McCausland K, Nonkwelo R, Mgudlwa B, Chacko S,
Majeke B. Birth defects following exposure to efavirenz-based
antiretroviral therapy during pregnancy: a study at a regional
South African hospital. AIDS 2010; 24:283–289.
16. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS,
Tookey PA. Antiretroviral therapy and congenital abnormal-
ities in infants born to HIV-infected women in the UK and
Ireland, 1999–2007. AIDS 2009; 23:519–524.
17. Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH,
Abreu TF, et al. Pregnancy outcome in women infected with
HIV-1 receiving combination antiretroviral therapy before
versus after conception. Sex Transm Infect 2009; 85:82–87.
18. Rossouw T. Quantifying antiretroviral risk in pregnancy. S Afr
Med J 2007; 97:1014–1016.
19. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O,
Thomas AM, et al. Pregnancy rates and birth outcomes among
women on efavirenz-containing highly active antiretroviral
therapy in Botswana. J Acquir Immune Deﬁc Syndr 2007;
20. Floridia M, Tamburrini E, Ravizza M, Anzidei G, Tibaldi C,
Bucceri A, et al. Antiretroviral therapy at conception in preg-
nant women with HIV in Italy: wide range of variability and
frequent exposure to contraindicated drugs. Antivir Ther 2006;
21. Jeantils V, Khuong MA, Delassus JL, Honore P, Taverne B, Uzan
M, Tassi S. Efavirenz (Sustiva) in pregnancy: a study about 12
HIV patients [in French]. Gynecol Obstet Fertil 2006; 34:593–
22. Patel D, Thorne C, Fiore S, Newell ML. Does highly active
antiretroviral therapy increase the risk of congenital abnorm-
alities in HIV-infected women? J Acquir Immune Deﬁc Syndr
23. Batallan A MG, Levine M, Longuet P, Bodard M, Legac S,
In utero exposure to efavirenz: evaluation in children born
alive. 2nd IAS Conference on HIV Pathogenesis and Treatment;
13–16 July 2003; Paris, France. Abstract 1100.
24. Laher F FJ, Mohapi L, Gray G. Efavirenz Conceptions in Soweto,
South Africa. 5th IAS Conference on HIV Pathogenesis, Treat-
ment and Prevention; 19–22 July 2009; Cape Town, South
Africa. Abstract TUPEC047.
25. Global report on birth defects. March of Dimes Birth Defects
Foundation White Plains: New York; 2006. http://wwwmarch
2304 AIDS 2011, Vol 25 No 18